多中心国际研究评估不可逆电穿孔消融前列腺癌的安全性、功能与肿瘤学结局
多中心前瞻性登记研究纳入411例局限性前列腺癌患者接受不可逆电穿孔(IRE)治疗,中位随访24个月。1年内重复穿刺活检显示临床显著前列腺癌(Gleason≥3+4)检出率24.1%(28/116),任何级别前列腺癌59.5%(69/116)。IPSS在3个月从7.1升至8.2(p=0.015)后6个月降至6.1(p=0.017);IIEF-5在3个月从16.0降至12.1(p<0.001)。不良事件率3个月为1.8%,6个月降至<1%并稳定至48个月。
要点
- IRE治疗后1年内重复活检临床显著前列腺癌检出率为24.1%(28/116)。
- IPSS在3个月从7.1升至8.2(p=0.015),6个月降至6.1(p=0.017)。
- IIEF-5在3个月从16.0降至12.1(p<0.001),之后保持稳定。
核心结论
- 对于局限性前列腺癌男性,IRE可获得良好的排尿与性功能结局和合理的肿瘤学结果。
- 真实世界数据与包括近期发表的随机对照研究在内的早期研究一致。
- 长期肿瘤学结果需要进一步研究和随访。
研究设计与样本
- 多中心前瞻性登记研究,招募组织学确诊的前列腺癌男性接受IRE治疗。
- 2015年7月至2020年4月共招募411例患者,中位随访24个月(IQR 15-36)。
- 所有患者计划在IRE消融后1年进行前列腺活检,116例患者在IRE后12-18个月接受了重复前列腺活检。
- 功能结局采用国际前列腺症状评分(IPSS)和国际勃起功能指数(IIEF-5)问卷测量。
- 安全性按常见不良事件术语标准(CTCAE)对治疗相关不良事件(AEs)分级。
主要发现
- 临床显著前列腺癌(Gleason≥3+4)在24.1%(28/116)的患者中检出;任何级别前列腺癌在59.5%(69/116)的患者中发现。
- IPSS评分在3个月从7.1显著升至8.2(p=0.015),但在6个月降至6.1(p=0.017),此后随访期间保持稳定。
- IIEF-5评分在3个月从16.0降至12.1(p<0.001),之后保持平稳。
- 不良事件率在3个月为1.8%,6个月降至<1%,并保持稳定至IRE后48个月。
- 主要不良事件(3级或以上)罕见。
临床怎么用
- 原文未据此给出推荐。
局限性
- 长期肿瘤学结果需要进一步研究和随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Irreversible electroporation (IRE) is a novel technique to treat localized prostate cancer with the aim of achieving oncological control while reducing related side effects. We present the outcomes of localized prostate cancer treated with IRE from a multi-center prospective registry. METHODS: Men with histologically confirmed prostate cancer were recruited to receive IRE. All the patients were proposed for prostate biopsy at 1-year post-IRE ablation. The functional outcomes were measured by the International Prostate Symptom Score (IPSS) and International Index of Erectile Function (IIEF-5) questionnaires. The safety of IRE was graded by the treatment-related adverse events (AEs) according to the Common Terminology Criteria for Adverse Events (CTCAE). RESULTS: 411 patients were recruited in this study from July 2015 to April 2020. The median follow-up time was 24 months (IQR 15-36). 116 patients underwent repeat prostate biopsy during 12-18 months after IRE. Clinically significant prostate cancer (Gleason ≥ 3 + 4) was detected in 24.1% (28/116) of the patients; any grade prostate cancers were found in 59.5% (69/116) of the patients. The IPSS score increased significantly from 7.1 to 8.2 (p = 0.015) at 3 months but decreased to 6.1 at 6 months (p = 0.017). Afterwards, the IPSS level remained stable during follow-up. The IIEF-5 score decreased at 3 months from 16.0 to 12.1 (p < 0.001) and then maintained equable afterwards. The rate of AEs was 1.8% at 3 months and then dropped to less than 1% at 6 months and remained stable until 48 months after IRE. Major AEs (Grade 3 or above) were rare. CONCLUSION: For men with localized prostate cancer, IRE could achieve good urinary and sexual function outcomes and a reasonable oncological result. The real-world data are consistent with earlier studies, including recently published randomized controlled studies. The long-term oncological results need further investigation and follow-up.
引用
- Zhang K, Stricker P, Löhr M, et al. A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer. Prostate Cancer Prostatic Dis. 2024. PMID: 38195916. doi:10.1038/s41391-023-00783-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。